百奥泰所属申万行业为：医药生物-生物制品-其他生物制品。所属概念板块包括：创新药、抗癌治癌、 抗癌药物、生物医药、融资融券等。 截至9月30日，百奥泰股东户数9397.00，较上期减少0.89%；人均流通股44065股，较上期增加0.89%。 2025年1月-9月，百奥泰实现营业收入6.84亿元，同比增长17.57%；归母净利润-2.24亿元，同比增长 38.72%。 11月25日，百奥泰盘中上涨2.15%，截至09:39，报25.63元/股，成交603.33万元，换手率0.06%，总市值 106.13亿元。 资金流向方面，主力资金净流出49.39万元，大单买入49.37万元，占比8.18%，卖出98.75万元，占比 16.37%。 百奥泰今年以来股价涨32.25%，近5个交易日跌1.65%，近20日跌6.43%，近60日跌21.60%。 资料显示，百奥泰生物制药股份有限公司位于广东省广州市国际生物岛螺旋二路18号，成立日期2003年 7月28日，上市日期2020年2月21日，公司主营业务涉及从事创新药和生物类似药的研发、生产业务。主 营业务收入构成为：药品销售业务91.90%，授权许可业务6.55%，代加工 ...

Core Viewpoint - Qianhong Biopharma's stock price has shown significant volatility, with a year-to-date increase of 38.42%, but recent declines in the short term indicate potential market concerns [1][2]. Company Overview - Qianhong Biopharma, established on April 30, 2003, and listed on February 18, 2011, is located in Changzhou, Jiangsu Province. The company specializes in the research, production, and sales of various pharmaceutical products, including lyophilized powders, injections, tablets, and active pharmaceutical ingredients [2]. - The company's main revenue sources are from its formulation series (62.97%) and active pharmaceutical ingredients (36.70%), with a minor contribution from other products (0.33%) [2]. Financial Performance - For the period from January to September 2025, Qianhong Biopharma reported a revenue of 1.215 billion yuan, reflecting a year-on-year growth of 0.61%. The net profit attributable to the parent company was 383 million yuan, marking a significant increase of 23.79% [2]. - The company has distributed a total of 1.862 billion yuan in dividends since its A-share listing, with 453 million yuan distributed over the past three years [2]. Market Activity - As of November 24, Qianhong Biopharma's stock price was 8.42 yuan per share, with a market capitalization of 10.776 billion yuan. The stock experienced a trading volume of 101 million yuan and a turnover rate of 1.29% [1]. - The stock has been active on the "Dragon and Tiger List" seven times this year, indicating notable trading interest, with the most recent appearance on August 7, where it recorded a net buy of 10.2288 million yuan [1]. Shareholder Information - As of September 30, 2025, the number of shareholders increased to 73,600, with an average of 12,785 circulating shares per person, a slight decrease of 1.15% from the previous period [2]. - The second-largest circulating shareholder is Hong Kong Central Clearing Limited, holding 49.0352 million shares, which increased by 19.8701 million shares compared to the previous period [2].

Core Insights - Huason Pharmaceutical's stock price increased by 2.09% on November 24, reaching 16.13 CNY per share, with a market capitalization of 6.736 billion CNY [1] - The company has seen a year-to-date stock price increase of 24.89%, but has experienced declines of 4.27% over the last five trading days, 5.06% over the last 20 days, and 12.50% over the last 60 days [2] - As of September 30, 2025, Huason Pharmaceutical reported a revenue of 626 million CNY, a year-on-year growth of 1.90%, while net profit attributable to shareholders decreased by 2.84% to 72.46 million CNY [3] Financial Performance - The company has made cumulative cash distributions of 192 million CNY since its A-share listing, with 100 million CNY distributed in the last three years [4] - As of September 30, 2025, the number of shareholders increased to 33,100, with an average of 9,063 circulating shares per shareholder, a decrease of 0.83% from the previous period [3] Business Overview - Huason Pharmaceutical, established on November 4, 1996, operates in the pharmaceutical industry, focusing on drug research, production, and sales [2] - The company's revenue composition includes 34.24% from otolaryngology drugs, 23.16% from digestive system drugs, 18.37% from psychiatric and neurological drugs, 15.02% from pharmaceutical commerce, and 7.76% from other fields [2] - The company is categorized under the pharmaceutical and biological industry, specifically in traditional Chinese medicine and related concepts such as innovative drugs and generic drugs [2]

Core Viewpoint - Nuo Cheng Jian Hua's stock price has shown significant volatility, with a year-to-date increase of 94.22%, but a recent decline of 3.68% over the last five trading days, indicating potential market fluctuations and investor sentiment shifts [2]. Company Overview - Nuo Cheng Jian Hua, established on November 3, 2015, and listed on September 21, 2022, is a Chinese biopharmaceutical company focused on the research, production, and commercialization of drugs, particularly in oncology and autoimmune diseases [2]. - The company's product pipeline includes ICP-022, ICP-B04, ICP-490, ICP-192, and ICP-723, targeting unmet clinical needs [2]. - The revenue composition is primarily from drug sales (87.67%), followed by technology licensing (12.04%), and minimal contributions from testing and R&D services (0.15% each) [2]. Financial Performance - For the period from January to September 2025, Nuo Cheng Jian Hua reported a revenue of 1.115 billion yuan, reflecting a year-on-year growth of 59.85%, while the net profit attributable to shareholders was a loss of 64.415 million yuan, an improvement of 76.61% compared to the previous period [3]. - As of September 30, 2025, the number of shareholders increased by 8.66% to 16,500, indicating growing interest in the company [3]. Shareholder Composition - The top ten circulating shareholders include notable funds such as Fu Guo Precision Medical Flexible Allocation Mixed A and Wan Jia You Xuan, with some new entrants and changes in holdings among existing shareholders [3].

Core Viewpoint - Kelong Pharmaceutical's stock price has shown fluctuations, with a year-to-date increase of 11.42%, but recent declines over various trading periods indicate potential volatility in investor sentiment [1][2]. Company Overview - Kelong Pharmaceutical, established on May 29, 2002, and listed on June 3, 2010, is based in Chengdu, Sichuan Province. The company specializes in the development, production, and sales of large-volume infusion products [1]. - The revenue composition of Kelong Pharmaceutical includes: non-infusion products (48.37%), infusion products (41.28%), research and development projects (7.01%), and others (3.33%) [1]. Financial Performance - For the period from January to September 2025, Kelong Pharmaceutical reported a revenue of 13.277 billion yuan, a year-on-year decrease of 20.92%. The net profit attributable to shareholders was 1.201 billion yuan, down 51.41% year-on-year [2]. - Cumulatively, Kelong Pharmaceutical has distributed 6.898 billion yuan in dividends since its A-share listing, with 3.587 billion yuan distributed over the past three years [3]. Shareholder Information - As of September 30, 2025, Kelong Pharmaceutical had 37,100 shareholders, an increase of 8.35% from the previous period. The average number of circulating shares per shareholder was 35,200, a decrease of 7.70% [2]. - The top ten circulating shareholders include various funds, with notable changes in holdings, such as a decrease in shares held by major institutional investors [3].

Core Viewpoint - Nanmo Bio has experienced significant stock price fluctuations in 2023, with a year-to-date increase of 79.28% but recent declines in the short term [1] Company Overview - Nanmo Bio, officially known as Shanghai Nanmo Biological Technology Co., Ltd., was established on September 20, 2000, and went public on December 28, 2021 [1] - The company specializes in the research, production, and sales of genetically modified animal models and related technical services [1] - Revenue composition includes standardized models (48.34%), model technical services (21.92%), model breeding (19.50%), customized models (9.34%), and others (0.91%) [1] Financial Performance - For the period from January to September 2025, Nanmo Bio reported a revenue of 303 million yuan, representing a year-on-year growth of 14.29% [2] - The net profit attributable to shareholders reached 26.76 million yuan, showing a substantial year-on-year increase of 276.14% [2] Shareholder Information - As of September 30, 2025, the number of shareholders increased by 2.53% to 6,687, while the average circulating shares per person decreased by 2.47% to 11,658 shares [2] - Since its A-share listing, Nanmo Bio has distributed a total of 30.04 million yuan in dividends, with 10.00 million yuan distributed over the past three years [3] - Among the top ten circulating shareholders, Tianhong Medical Health A is a new entrant, holding 377,400 shares [3]

11月21日，三生国健盘中下跌2.04%，截至10:23，报64.28元/股，成交1.24亿元，换手率0.31%，总市值 396.47亿元。 资金流向方面，主力资金净流入200.37万元，特大单买入951.74万元，占比7.70%，卖出511.46万元，占 比4.14%；大单买入2717.60万元，占比21.98%，卖出2957.52万元，占比23.92%。 三生国健今年以来股价涨201.83%，近5个交易日跌11.18%，近20日涨17.31%，近60日涨20.86%。 今年以来三生国健已经7次登上龙虎榜，最近一次登上龙虎榜为11月3日。 三生国健所属申万行业为：医药生物-生物制品-其他生物制品。所属概念板块包括：生物医药、融资融 券、增持回购、中盘、抗癌药物等。 截至9月30日，三生国健股东户数1.12万，较上期减少12.77%；人均流通股55060股，较上期增加 14.64%。2025年1月-9月，三生国健实现营业收入11.16亿元，同比增长18.80%；归母净利润3.99亿元， 同比增长71.15%。 分红方面，三生国健A股上市后累计派现1.27亿元。 机构持仓方面，截止2025年9月30日，三生国健 ...

Core Viewpoint - Nocare Biopharma's stock has experienced fluctuations, with a year-to-date increase of 92.83% but a recent decline of 6.55% over the past five trading days [1] Company Overview - Nocare Biopharma, established on November 3, 2015, and listed on September 21, 2022, is based in Beijing and focuses on the research, production, and commercialization of biopharmaceuticals, particularly in oncology and autoimmune diseases [1] - The company's revenue composition includes 87.67% from drug sales, 12.04% from technology licensing, and 0.15% each from testing and research services [1] Financial Performance - For the period from January to September 2025, Nocare Biopharma reported revenue of 1.115 billion yuan, reflecting a year-on-year growth of 59.85%, while the net profit attributable to shareholders was -64.41 million yuan, an increase of 76.61% year-on-year [2] Shareholder Information - As of September 30, 2025, the number of shareholders increased by 8.66% to 16,500, with an average of 0 circulating shares per person [2] - The top ten circulating shareholders include several new entrants, such as Wanjiayou Xuan and Ping An Healthcare, while some previous shareholders have exited the list [3]

Core Viewpoint - Zai Lab's stock price has shown significant volatility, with a year-to-date increase of 64.82%, but a recent decline of 3.11% over the past five trading days, indicating potential market fluctuations and investor sentiment shifts [1][2]. Company Overview - Zai Lab, established on March 18, 2009, and listed on January 23, 2020, is based in Kunshan, Jiangsu Province, focusing on the research, production, and sales of chemical and biological new drugs [1]. - The company's main revenue source is pharmaceuticals, accounting for 99.97% of its business, with minimal contributions from intermediates and asset leasing [1]. Financial Performance - For the period from January to September 2025, Zai Lab reported a revenue of 593 million yuan, reflecting a year-on-year growth of 54.49%. However, the net profit attributable to shareholders was a loss of 93.42 million yuan, showing a slight increase in loss of 4.58% compared to the previous period [2]. Shareholder Structure - As of September 30, 2025, Zai Lab had 8,809 shareholders, a slight increase of 0.16% from the previous period. The average number of circulating shares per shareholder decreased by 0.16% to 30,049 shares [2]. - Notable institutional shareholders include China Europe Medical Health Mixed A and ICBC Frontier Medical Stock A, with varying changes in their holdings [2].

Core Viewpoint - Benda Pharmaceutical's stock has experienced a decline in recent trading sessions, with a notable drop in both share price and market capitalization, indicating potential challenges in the company's performance and investor sentiment [1][2]. Company Performance - As of September 30, Benda Pharmaceutical reported a revenue of 2.717 billion yuan, reflecting a year-on-year growth of 15.90%. However, the net profit attributable to shareholders decreased by 23.86% to 317 million yuan [2]. - The company's stock price has fallen by 5.40% year-to-date, with a 5.71% decline over the past five trading days, a 12.75% drop over the last 20 days, and a significant 27.60% decrease over the past 60 days [1]. Shareholder Information - The number of shareholders decreased by 7.99% to 29,500, while the average number of circulating shares per person increased by 8.68% to 14,198 shares [2]. - Benda Pharmaceutical has distributed a total of 669 million yuan in dividends since its A-share listing, with 184 million yuan distributed over the past three years [3]. Institutional Holdings - As of September 30, 2025, notable institutional shareholders include Xingquan Commercial Model Mixed Fund (LOF) A, which is the fifth-largest shareholder with 5.827 million shares, and E-Fund's Growth Enterprise Board ETF, which has reduced its holdings by 912,300 shares [3].